Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
Hanjie Yi(Nanchang University), Dajun Yang(Ascendis Pharma (Denmark))
Cited by 49
Related Papers
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients
|BMC Cancer|2014|70
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
|Journal of Experimental & Clinical Cancer Research|2018|70
Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy
|Supportive Care in Cancer|2014|66